| 本文已被：浏览 58次 下载 23次 |
码上扫一扫！ |
| 靶向治疗和免疫治疗在肝细胞癌转化治疗中的研究进展 |
| 吕玻玮1,沈皓2,田淏1,夏勇2,沈锋1,2,3* |
|
|
(1. 广东药科大学第一临床医学院, 广州 510006;
2. 海军军医大学(第二军医大学)第三附属医院肝外四科, 上海 200438;
3. 海军军医大学(第二军医大学)第三附属医院临床研究院, 上海 200438
*通信作者) |
|
| 摘要: |
| 肝细胞癌（HCC）是一种遍布全球的恶性肿瘤，其发病率和死亡率常年位居前列。由于其发病隐匿，大部分患者确诊时已处于晚期，通过转化治疗改善患者预后、提高生存率已成为当前医学领域的研究热点。近年来，随着生物技术和药物研发的不断进步，以靶向和免疫治疗药物为代表的新型治疗被广泛用于HCC转化治疗。相较其他转化治疗方案，这些药物能有效延长患者无进展生存期、总生存期，且具有不良反应可控等优势。此外，靶向药物与免疫治疗药物的联合治疗在提高HCC患者的生存收益方面也发挥了积极作用。本文旨在综述靶向治疗和免疫治疗在HCC一线和二线治疗中的最新研究进展，并探讨其安全性和未来发展方向。 |
| 关键词: 肝肿瘤 肝细胞癌 转化治疗 分子靶向治疗 免疫疗法 |
| DOI：10.16781/j.CN31-2187/R.20240431 |
| 投稿时间：2024-06-17修订日期：2024-12-26 |
| 基金项目:国家资助博士后人员项目（GZC20231943），上海市申康医院发展中心示范性研究型病房建设项目（SHDC2023CRW002）. |
|
| Targeted therapy and immunotherapy in conversion therapy of hepatocellular carcinoma: research progress |
| Lü Bowei1,SHEN Hao2,TIAN Hao1,XIA Yong2,SHEN Feng1,2,3* |
(1. The First Clinical Medical College, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China;
2. Department of Hepatic Surgery (Ⅳ), The Third Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200438, China;
3. Clinical Research Institute, The Third Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200438, China
*Corresponding author) |
| Abstract: |
| Hepatocellular carcinoma (HCC) is a common malignant tumor worldwide, and its incidence and mortality are among the highest for many years. Due to its insidious onset, most patients are already at advanced stages when diagnosed. Improving the prognosis and survival rate of patients through conversion therapy has become a research focus lately. In recent years, with the continuous progress of biotechnology and drug development, new therapies represented by targeted and immunotherapy drugs have been widely used in HCC conversion therapy. Compared with other conversion therapy regimens, these drugs can effectively prolong the progression free survival and overall survival of patients and have advantages such as controllable adverse reactions. In addition, the combination of targeted drugs and immunotherapy drugs also plays a positive role in improving the survival benefit of HCC patients. This article aims to review the latest research progress of targeted therapy and immunotherapy in the first- and second-line treatments of HCC, and to discuss their safety and future development. |
| Key words: liver neoplasms hepatocellular carcinoma conversion therapy molecular targeted therapy immunotherapy |
